Investor and Analyst Webcast with Expert Oncologists
Date and Time:
Dial-in: +1 877-407-2988 for
Investors and analysts can also view slides and listen to the live audio webcast of the presentation on the Investors section of Alkermes' website at www.alkermes.com. A replay of the webcast will be archived on the company's website for 30 days following the presentation.
Nemvaleukin Poster Presentations at ASCO
Abstract: 2513
Title: ARTISTRY-1: Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Presenter:
Presentation Date/Time: The on-demand poster discussion session will take place on
Abstract: 2552
Title: Selection of the Recommended Phase 2 Dose (RP2D) for Subcutaneous Nemvaleukin Alfa: ARTISTRY-2
Presenter:
Presentation Date: The poster presentation will be available on-demand to attendees beginning
About Nemvaleukin alfa ('nemvaleukin')
Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.
About the ARTISTRY Clinical Development Program
ARTISTRY is an Alkermes-sponsored clinical development program evaluating nemvaleukin alfa as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous and subcutaneous dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Ongoing trials include: ARTISTRY-1, ARTISTRY-2, ARTISTRY-3 and ARTISTRY-6.
About
KEYTRUDA is a registered trademark of
Contact:
Investors
T: +1 781 609 6377
Media
Sourojit Bhowmick, Ph.D.
T: +1 781 609 6397
(C) 2021 Electronic News Publishing, source